XTL BiopharmaceuticalsXTLB -7.99%24 Days Payable is 27.43 as of Jun. 2025, which is 66% below its 10-year median of 80.26. GuruFocus rates XTLB with a GF Score™ of 24/100. The stock has 2 warning signs investors should review. Among 706 Biotechnology companies, XTL Biopharmaceuticals ranks worse than 75.5% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, XTL Biopharmaceuticals's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
XTL Biopharmaceuticals Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, XTL Biopharmaceuticals's Days Payable distribution charts can be found below:
* The bar in red indicates where XTL Biopharmaceuticals's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
XTL Biopharmaceuticals's Days Payable for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XTL Biopharmaceuticals (XTLB) has a Days Payable of 27.43 as of Jun. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on XTL Biopharmaceuticals and its competitors. This is 66% below median its historical median of 80.26. Over the past decade, XTL Biopharmaceuticals' Days Payable has ranged from 37.73 to 80.26. According to the industry distribution chart, XTL Biopharmaceuticals ranks #533 out of 706 companies in the Biotechnology industry, placing it in the top 75.5%.
Is XTL Biopharmaceuticals' Days Payable too high?
XTL Biopharmaceuticals' current Days Payable of 27.43 is 66% below median its 10-year median of 80.26. Over the past 10 years, this metric has ranged from a low of 37.73 to a high of 80.26. The Biotechnology industry median Days Payable is 113.56. XTL Biopharmaceuticals' value of 27.43 is 75.8% below this industry median. Based on the distribution chart, XTL Biopharmaceuticals ranks #533 out of 706 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, XTL Biopharmaceuticals has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does XTL Biopharmaceuticals' Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, XTL Biopharmaceuticals ranks #533 out of 706 companies for Days Payable. This places XTL Biopharmaceuticals in the lower half of its industry. The industry median Days Payable is 113.56. XTL Biopharmaceuticals' value of 27.43 is 75.8% below this benchmark. Historically, XTL Biopharmaceuticals' own Days Payable has ranged from 37.73 to 80.26 over the past decade. While the company's 10-year median is 80.26 vs. the industry median of 113.56, XTL Biopharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.56, based on 706 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. XTL Biopharmaceuticals's current Days Payable of 27.43 is 75.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on XTL Biopharmaceuticals and its competitors. For the Biotechnology industry, the median Days Payable is 113.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. XTL Biopharmaceuticals's current Days Payable is 27.43, which is 66% below median its own 10-year median of 80.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is XTL Biopharmaceuticals stock overvalued right now?
XTL Biopharmaceuticals (XTLB) has a current Days Payable of 27.43. The current Days Payable is 27.43, which is 66% below median its 10-year median of 80.26 and 75.8% below the Biotechnology industry median of 113.56. XTL Biopharmaceuticals' overall GF Score™ is 24/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For XTL Biopharmaceuticals (XTLB), the current Days Payable is 27.43 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.
24GF Score
Get the complete analysis for XTLB
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTLB has been successfully added to your 
